Literature DB >> 10482571

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

P S Polacino1, V Stallard, J E Klaniecki, S Pennathur, D C Montefiori, A J Langlois, B A Richardson, W R Morton, R E Benveniste, S L Hu.   

Abstract

We previously showed that envelope (gp160)-based vaccines, used in a live recombinant virus priming and subunit protein boosting regimen, protected macaques against intravenous and intrarectal challenges with the homologous simian immunodeficiency virus SIVmne clone E11S. However, the breadth of protection appears to be limited, since the vaccines were only partially effective against intravenous challenge by the uncloned SIVmne. To examine factors that could affect the breadth and the efficacy of this immunization approach, we studied (i) the effect of priming by recombinant vaccinia virus; (ii) the role of surface antigen gp130; and (iii) the role of core antigens (Gag and Pol) in eliciting protective immunity. Results indicate that (i) priming with recombinant vaccinia virus was more effective than subunit antigen in eliciting protective responses; (ii) while both gp130 and gp160 elicited similar levels of SIV-specific antibodies, gp130 was not as effective as gp160 in protection, indicating a possible role for the transmembrane protein in presenting functionally important epitopes; and (iii) although animals immunized with core antigens failed to generate any neutralizing antibody and were infected upon challenge, their virus load was 50- to 100-fold lower than that of the controls, suggesting the importance of cellular immunity or other core-specific immune responses in controlling acute infection. Complete protection against intravenous infection by the pathogenic uncloned SIVmne was achieved by immunization with both the envelope and the core antigens. These results indicate that immune responses to both antigens may contribute to protection and thus argue for the inclusion of multiple antigens in recombinant vaccine designs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482571      PMCID: PMC112838          DOI: 10.1128/JVI.73.10.8201-8215.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  99 in total

Review 1.  Role of cellular immunity in protection against HIV infection.

Authors:  S Rowland-Jones; R Tan; A McMichael
Journal:  Adv Immunol       Date:  1997       Impact factor: 3.543

2.  Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.

Authors:  P W Berman; A M Gray; T Wrin; J C Vennari; D J Eastman; G R Nakamura; D P Francis; G Gorse; D H Schwartz
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

3.  Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization.

Authors:  M D Lubeck; R Natuk; M Myagkikh; N Kalyan; K Aldrich; F Sinangil; S Alipanah; S C Murthy; P K Chanda; S M Nigida; P D Markham; S Zolla-Pazner; K Steimer; M Wade; M S Reitz; L O Arthur; S Mizutani; A Davis; P P Hung; R C Gallo; J Eichberg; M Robert-Guroff
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

4.  Long-term protection of macaques against high-dose type D retrovirus challenge after immunization with recombinant vaccinia virus expressing envelope glycoproteins.

Authors:  R E Benveniste; L Kuller; S T Roodman; S L Hu; W R Morton
Journal:  J Med Primatol       Date:  1993 Feb-May       Impact factor: 0.667

5.  Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein.

Authors:  P L Earl; B Moss
Journal:  AIDS Res Hum Retroviruses       Date:  1993-07       Impact factor: 2.205

6.  A chain section containing epitopes for cytotoxic T, B and helper T cells within a highly conserved region found in the human immunodeficiency virus type 1 Gag protein.

Authors:  Y Nakamura; M Kameoka; M Tobiume; M Kaya; K Ohki; T Yamada; K Ikuta
Journal:  Vaccine       Date:  1997-04       Impact factor: 3.641

7.  Expression of AIDS virus envelope gene in recombinant vaccinia viruses.

Authors:  S L Hu; S G Kosowski; J M Dalrymple
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

8.  Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160.

Authors:  S L Hu; V Stallard; K Abrams; G N Barber; L Kuller; A J Langlois; W R Morton; R E Benveniste
Journal:  J Med Primatol       Date:  1993 Feb-May       Impact factor: 0.667

9.  Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Authors:  E L Cooney; M J McElrath; L Corey; S L Hu; A C Collier; D Arditti; M Hoffman; R W Coombs; G E Smith; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein.

Authors:  F Buseyne; M McChesney; F Porrot; S Kovarik; B Guy; Y Rivière
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  27 in total

1.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Authors:  C G Murphy; W T Lucas; R E Means; S Czajak; C L Hale; J D Lifson; A Kaur; R P Johnson; D M Knipe; R C Desrosiers
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

4.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

5.  DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.

Authors:  Mariana Manrique; Ewa Micewicz; Pamela A Kozlowski; Shainn-Wei Wang; Deepti Aurora; Robert L Wilson; Musie Ghebremichael; Gail Mazzara; David Montefiori; Angela Carville; Keith G Mansfield; Anna Aldovini
Journal:  AIDS Res Hum Retroviruses       Date:  2008-03       Impact factor: 2.205

Review 6.  Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.

Authors:  Mevyn Nizard; Mariana O Diniz; Helene Roussel; Thi Tran; Luis Cs Ferreira; Cecile Badoual; Eric Tartour
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.

Authors:  A Seth; I Ourmanov; J E Schmitz; M J Kuroda; M A Lifton; C E Nickerson; L Wyatt; M Carroll; B Moss; D Venzon; N L Letvin; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

10.  Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.

Authors:  Jun Zhao; Joel Pinczewski; Victor R Gómez-Román; David Venzon; V S Kalyanaraman; Phillip D Markham; Kristine Aldrich; Matthew Moake; David C Montefiori; Yuanmei Lou; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.